EVG7
Disambiguating links to NWO (link changed to Dutch Research Council) using DisamAssist.
| ← Previous revision | Revision as of 20:28, 20 April 2026 | ||
| Line 52: | Line 52: | ||
Development of EVG7 began around 2017, when Nathaniel Martin's group at Leiden University started exploring new chemical approaches to modify the structure of vancomycin. Vancomycin is a naturally occurring glycopeptide antibiotic that has been used in hospitals for decades, but it carries a risk of [[nephrotoxicity|kidney damage]] and faces growing problems with [[antimicrobial resistance|bacterial resistance]].{{cite web | title = Powerful New Antibiotic May Help Overcome Resistance | date = 9 August 2024 | url = https://www.technologynetworks.com/drug-discovery/news/powerful-new-antibiotic-may-help-overcome-resistance-389644 | website = Technology Networks | access-date = 15 March 2026 }} PhD candidate Emma van Groesen synthesised around one hundred structural variants of vancomycin using a specific chemical modification strategy, out of which the seventh compound, designated EVG7, proved to be the most active. |
Development of EVG7 began around 2017, when Nathaniel Martin's group at Leiden University started exploring new chemical approaches to modify the structure of vancomycin. Vancomycin is a naturally occurring glycopeptide antibiotic that has been used in hospitals for decades, but it carries a risk of [[nephrotoxicity|kidney damage]] and faces growing problems with [[antimicrobial resistance|bacterial resistance]].{{cite web | title = Powerful New Antibiotic May Help Overcome Resistance | date = 9 August 2024 | url = https://www.technologynetworks.com/drug-discovery/news/powerful-new-antibiotic-may-help-overcome-resistance-389644 | website = Technology Networks | access-date = 15 March 2026 }} PhD candidate Emma van Groesen synthesised around one hundred structural variants of vancomycin using a specific chemical modification strategy, out of which the seventh compound, designated EVG7, proved to be the most active. |
||
The project has been supported by two grants from the Dutch Research Council ([[NWO]]) NACTAR programme (Novel Antibacterial Compounds and Therapies Antagonising Resistance), a joint initiative with the Dutch Ministry of Health, Welfare and Sport aimed at bringing new antibiotics into (pre-)clinical testing.{{cite web | title = Four research projects into new antibiotics to start | url = https://www.nwo.nl/en/news/four-research-projects-into-new-antibiotics-to-start | website = NWO | access-date = 15 March 2026 }}{{cite web | title = VALIANT - VALIdation of a Novel Glycopeptide ANTibiotic with Best-in-Class Potential | url = https://www.nwo.nl/en/projects/20813 | website = NWO | access-date = 15 March 2026 }} Preclinical pharmacology studies are being conducted in collaboration with Coen van Hasselt of the Leiden Academic Centre for Drug Research (LACDR). |
The project has been supported by two grants from the Dutch Research Council ([[Dutch Research Council|NWO]]) NACTAR programme (Novel Antibacterial Compounds and Therapies Antagonising Resistance), a joint initiative with the Dutch Ministry of Health, Welfare and Sport aimed at bringing new antibiotics into (pre-)clinical testing.{{cite web | title = Four research projects into new antibiotics to start | url = https://www.nwo.nl/en/news/four-research-projects-into-new-antibiotics-to-start | website = NWO | access-date = 15 March 2026 }}{{cite web | title = VALIANT - VALIdation of a Novel Glycopeptide ANTibiotic with Best-in-Class Potential | url = https://www.nwo.nl/en/projects/20813 | website = NWO | access-date = 15 March 2026 }} Preclinical pharmacology studies are being conducted in collaboration with Coen van Hasselt of the Leiden Academic Centre for Drug Research (LACDR). |
||
== Chemistry and mechanism of action == |
== Chemistry and mechanism of action == |
||
